Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $58.6 million.

  • Phathom Pharmaceuticals' Operating Expenses fell 3090.74% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.9 million, marking a year-over-year increase of 1033.59%. This contributed to the annual value of $324.7 million for FY2024, which is 9350.04% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Operating Expenses of $58.6 million as of Q3 2025, which was down 3090.74% from $94.4 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Operating Expenses registered a high of $103.7 million during Q1 2025, and its lowest value of $30.1 million during Q1 2023.
  • In the last 4 years, Phathom Pharmaceuticals' Operating Expenses had a median value of $58.6 million in 2025 and averaged $61.4 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 16260.37% in 2024, then tumbled by 3090.74% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Operating Expenses stood at $46.6 million in 2022, then soared by 50.92% to $70.4 million in 2023, then rose by 21.13% to $85.3 million in 2024, then plummeted by 31.29% to $58.6 million in 2025.
  • Its Operating Expenses was $58.6 million in Q3 2025, compared to $94.4 million in Q2 2025 and $103.7 million in Q1 2025.